www.bjcancer.com

Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification

MJ Smith^{1,2}, AC Culhane^{3,4}, M Donovan², JC Coffey¹, BD Barry¹, MA Kelly¹, DG Higgins⁵, JH Wang¹, WO Kirwan¹, TG Cotter² and HP Redmond^{*,1}

¹Department of Academic Surgery, University College Cork, Cork, Ireland; ²Department of Biochemistry, University College Cork, Cork, Ireland; ³Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; ⁴Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA; ⁵Conway Institute, University College Dublin, Belfield, Dublin, Ireland

Tumour stroma gene expression in biopsy specimens may obscure the expression of tumour parenchyma, hampering the predictive power of microarrays. We aimed to assess the utility of fluorescence-activated cell sorting (FACS) for generating cell populations for gene expression analysis and to compare the gene expression of FACS-purified tumour parenchyma to that of whole tumour biopsies. Single cell suspensions were generated from colorectal tumour biopsies and tumour parenchyma was separated using FACS. Fluorescence-activated cell sorting allowed reliable estimation and purification of cell populations, generating parenchymal purity above 90%. RNA from FACS-purified and corresponding whole tumour biopsies was hybridised to Affymetrix oligonucleotide microarrays. Whole tumour and parenchymal samples demonstrated differential gene expression (e.g., *COL6A3, COL1A2, POSTN, TIMP2*). Genes characteristic of colorectal carcinoma were overexpressed in the FACS-purified cells (e.g., *HOX2D* and *RHOB*). We found FACS to be a robust method for generating samples for gene expression analysis, allowing simultaneous assessment of parenchymal and stromal compartments. Gross stromal contamination may affect the interpretation of cancer gene expression microarray experiments, with implications for hypotheses generation and the stability of expression signatures used for predicting clinical outcomes.

British Journal of Cancer (2009) 100, 1452–1464. doi:10.1038/sj.bjc.6604931 www.bjcancer.com © 2009 Cancer Research UK

Keywords: colorectal cancer; fluorescence-activated cell sorting; gene expression microarray analysis; humans

Gene expression microarray data have huge potential for cancer research and treatment. Gene expression profiles have been used to classify tumours (Bittner et al, 2000; Ramaswamy et al, 2001; Selaru et al, 2002; Shipp et al, 2002), study the biology of tumour progression and metastasis (Birkenkamp-Demtroder et al, 2002; Ramaswamy et al, 2003), predict clinical outcomes (van de Vijver et al, 2002; Huang et al, 2003; Iizuka et al, 2003), classify drug resistance (Hofmann et al, 2002; Chang et al, 2003) and identify novel drug targets (Marton et al, 1998). As the technology matures, it is pushing towards mainstream clinical application (Gershon, 2004; Jarvis and Centola, 2005; Cardoso et al, 2008). Surmountable challenges remain, such as standardisation and validation of the competing platforms and analysis techniques. However, the heterogeneity of clinical tumour samples remains a fundamental problem which must be addressed (Winegarden, 2003). All cell subpopulations in a sample contribute to the gene expression profile. Relatively homogenous cell populations yield optimal expression data, and increasing ratios of stromal cells may obscure the gene expression of parenchymal cancer cells (Emmert-Buck

et al, 1996; Ross *et al*, 2000; Butte, 2002; Sugiyama *et al*, 2002). Stromal gene expression may cause misinterpretation of data, with important subtle cancer gene changes being masked by contaminating RNA, and increasing the potential for attributing incorrect functional gene associations (Smith *et al*, 2003). However, interactions between stromal cells and tumour parenchyma are increasingly recognised as an important factor in tumour biology and clinical outcome, and the delineation and retention of stromal gene expression has considerable value (Fukino *et al*, 2007; Patocs *et al*, 2007).

Laser capture microdissection (LCM) allows the selection of specific cells from tissue and could potentially circumvent many of these problems (Emmert-Buck et al, 1996). Sugiyama et al (2002) examined the expression profile of LCM dissected tissue and whole tissue. They demonstrated significant differences in expression profiles, finding that the overall difference in the gene expression profile was related to levels of stromal contamination. However, LCM is a costly, laborious and highly skilled procedure which yields small quantities of RNA, which renders clinical application impractical (Liu, 2007). It has also been demonstrated by Michel et al (2003) that the LCM process introduces a systematic bias into gene expression profiles. Another problem encountered in the estimation of stromal content histologically, and therefore by both LCM and macrodissection, is the 'reference trap'. A two-dimensional microscopic view of a complex three-dimensional structure, such as a tumour, leads to irreversible qualitative and quantitative

^{*}Correspondence: Professor HP Redmond, Department of Academic Surgery, University College Cork, Cork University Hospital, Wilton, Cork, Ireland; E-mail: Henry.Redmond@hse.ie

Received 15 September 2008; revised 3 December 2008; accepted 15 January 2009

 Table I
 Microarray sample details

Dissociated cells in suspension were incubated on ice with mouse anti-human epithelial antigen (HEA) monoclonal antibody (mAb) conjugated with FITC (clone BER-EP4; Dako, Glostrup, Denmark), anti-CD14 mAb conjugated with phycoerythrin (PE) and anti-CD45 conjugated with PerCP mAb (both from BD Pharmingen, Erembodegem-Aalst, Belgium) or relevant isotype controls, for 45 min. The labelled cells were analysed and separated using FACS Vantage with CellQuest Pro software (Becton Dickinson). Establishment of the gates was based on the staining profiles of the negative controls, positive controls (SW-620 cells, labelled with HEA) and to eliminate low forward scatter signal events, eliminating debris, red cells and apoptotic cells.

The mAb BER-EP4 binds to a partially formol-resistant epitope on the protein moiety of two 34- and 39 kDa glycopolypeptides on human epithelial cells. It does not bind to any non-epithelial cells (Latza et al, 1990). Specifically, it does not bind to mesenchymal or lymphoid tissue. However, in large cell populations antibodies can bind in a non-specific manner. To control for this, we blocked antibodies with 1% fetal calf serum and used isotype control antibodies as negative controls. There is also a possibility of immune cells expressing the HEA antigen after ingestion of apoptotic cells. As immune cell infiltrate is a large component of stromal tissue, we decided to use antibodies to allow us to quantify and negatively select immune cells to avoid contamination in our sorted epithelial fraction. Phagocyte numbers have been found to increase from 1.5- to 2.5-fold in Duke's B and C tumours, respectively, and T cells by 1.4-fold in colorectal tumours (Allen and Hogg, 1985, 1987). We decided that a combination of antibodies binding to CD14, which is the LPS receptor and is expressed strongly on the surface of monocytes, weakly on the surface of granulocytes and by most tissue macrophages, and CD45, a tyrosine phosphatase a critical requirement for T- and B-cell antigen receptor-mediated activation, which is expressed, typically at high levels, on all haematopoietic cells (expression is at a higher density on lymphocytes, approximately 10% of surface area is CD45), would be the ideal combination. It has previously been demonstrated that using positive selection of HEA-expressing cells and negative selection of CD45- or CD14-expressing cells yields using immunomagnetic cell sorting lead to high yields of epithelial cells from cell solutions (Zigeuner et al, 2000; Guo et al, 2004).

Cell sorting and confirmation of cell phenotype

A one-step, three-colour, sorting approach was used. Our goal was to positively select colorectal parenchyma and negatively select for stromal cells. A diagram illustrating the method is shown in Figure 1. Sorting gates were set for positive selection of HEA^+ CD14⁻ CD45⁻ and negative selection of HEA^- CD14⁺ CD45⁺ cells. Unstained cells, cells stained with isotype controls, were used for all samples, and SW-620 cells were used as a positive control for CRC cells. At least 7 million HEA⁺ cells were sorted, as below this level we found RNA quantity was variable. Cells were sorted into BD polypropylene flow tubes coated with 4% bovine serum albumin (Sigma-Aldrich). Purity of the sample was checked after

loss of information (Nyengaard, 1999). This means that fractions of cells can be grossly under- or overestimated if unbiased sampling methods (i.e. stereological methods) are not used.

Fluorescence cytometry (FC) and fluorescence-activated cell sorting (FACS) allow simultaneous quantitation and multiparametric assessment of the phenotype of cells by staining with fluorochrome-conjugated antibodies (Afanasyeva et al, 2004). These are generally used to examine or sort peripheral blood samples (Waguri et al, 2003), to identify tumour cells in malignant effusions, to isolate clones and infrequently for the separation of specific cell populations from solid tissue (Afanasyeva et al, 2004; Suzuki et al, 2004). Advances in laser technology, speed of sorting and range of fluorochromes, make FACS a potentially useful method for identifying and purifying cell populations from solid tumours for analysis. Fluorescence-activated cell sorting overcomes many of the problems associated with LCM and macrodissection, by allowing systematic sampling of a large number of parenchymal tumour cells, allowing confirmation of the purity of targets and potentially, a better average of gene expression in cancer cells. We aimed to evaluate the feasibility of using FACS for producing homogenous cell populations for gene expression microarray analysis of colorectal tumour samples. Specifically, we wished to compare the differences in gene expression profiles elicited from whole tissue and sorted cells.

MATERIALS AND METHODS

Colorectal carcinoma tissue

Colorectal carcinoma (CRC) tissue samples were obtained, with informed consent, from patients undergoing curative bowel resection (Table 1). All patients were Irish Caucasians. None of the patients received preoperative chemotherapy or radiotherapy. Three primary cancers were used to compare the gene expression of sorted cells and whole tumour samples, after optimisation of our FACS methodology. Collection of tissue was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals.

Generation of a single cell suspension from colorectal cancer tissue

Tumour samples were washed in Dulbecco's modified Eagle's medium (DMEM; BioWhittaker, Wokingham, UK) and macroscopic necrotic tissue was excised with a scalpel and washed in DMEM. A portion of the biopsy was immediately snap frozen in liquid nitrogen and stored at -80° C until RNA extraction and approximately 1 g of tumour tissue was mechanically disaggregated, and subsequently enzymatically digested with bovine collagenase II, IV (Sigma-Aldrich, Dublin, Ireland) and DNAse I (Roche, Clarecastle, Ireland) at concentrations of 2 and 1 mg ml⁻¹, at room temperature (22°C) for 45–60 min. This mix was then filtered through 70 mm pore mesh (Becton Dickinson, Oxford, UK). All suspensions were generated under standardised environmental conditions, being kept at 4°C, except for the enzyme digestion stage.

CEL file name	Patient	Sample type	TNM classification	Stage	Location	Sex	Age (years)
A053-04-EI	EI	FACS	T4N0MI	IV	Caecum	Female	68
A053-03-E6	E6	FACS	T2N0Mx	I	Rectosigmoid	Male	55
A053-05-E12	EI2	FACS	T3N0Mx	IIA	Sigmoid	Male	35
A053-06-EIW	EI	Whole tissue	T4N0M1	IV	Caecum	Female	68
A053-07-E6W	E6	Whole tissue	T2N0Mx	I	Rectosigmoid	Male	55
A053-08-E12W	EI2	Whole tissue	T3N0Mx	IIA	Sigmoid	Male	35



sorting by reanalysing HEA $^+$ CD14 $^-$ CD45 $^-$ fraction, on the same machine, after a full cleaning protocol. Purity greater than 90% was deemed acceptable.

After sorting, cells were confirmed to be colorectal tumour cells by microscopic examination, by cytospinning on to Superfrost Plus

microscope slides (BDH Laboratory Supplies, Poole, UK) followed by ethanol fixation and staining with Rapi-Diff (Cytocolor, Hinckley, OH, USA) or immunocytochemistry. Immunocytochemistry was performed using Dako MNF-116 anti-pan-cytokeratin antibody, using the standard EnVision kit protocol (Dako).



Step 1. Gating out debris and identification of HEA positive population

Figure 1 This figure demonstrates our method for separating tumour stroma and parenchymal cells using fluorescence-activated cell sorting. Briefly, debris is gated out, target populations identified and positively (parenchyma) or negatively selected (stroma). Dot plots represent 10000 events, and show side scatter and forward scatter plots in Step 1 and fluorescence plots in Steps 2 and 3. Cells have been simultaneously stained with mouse anti-human anti-HEA, anti-CD14 and anti-CD45 monoclonal antibodies conjugated with FITC, PE and PerCP, respectively, which are resolved on FL-1, FL-2 and FL-3. Step 1 demonstrates our method of gating out debris and identification of the HEA positive population with scatter plots. Step 2 demonstrates the identification of CD45 (A) and CD14 (B) positive populations, followed by gating of the HEA+ CD45- population (C) and gating of the HEA+ CD14- CD45- population (D). Step 3 is the identification and the estimation of the pre-sorting parenchymal content (HEA+ CD14- CD45- population, R3 region), which is estimated at only 43% of cells in this sample, and the selection of the R3 region as a cell sorting gate. After cell sorting the fluorescence of HEA⁺ cells on FL-1 (region M2) against counts on the *y*-axis. There is clear separation of the tumour parenchyma (M2 region) and the stromal (M1 region) cells. We estimate the populations have a purity of over 90%.





Figure I Continued.

We have also applied this method to successfully purify tumour parenchyma in CRC liver metastases, primary breast tumours, and with modification, to sort breast cancer bone marrow micrometastases.

RNA isolation

RNA was extracted from three corresponding whole tumour samples and FACS-purified tumour parenchyma using a modification of the Tri Reagent (Molecular Research Center, Cincinnati, OH, USA) protocol (Curtin and Cotter, 2004). RNA with an absorbance ratio A260/240 >1.8 and no evidence of RNA degradation by gel electrophoresis was accepted. We then checked the RNA quality using the Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA) runs. We used RNA with a RIN (RNA integrity number) value ≥ 8 (Schroeder *et al*, 2006).

cRNA preparation

The labelling of the total RNA was performed according to the 'Small Sample Labeling Protocol vII' (Affymetrix, Santa Clara, CA, USA). Total RNA (100 ng) was used as starting material for the first round of cDNA preparation. The first and second strand cDNA synthesis was performed using the Superscript II system (Invitrogen, Dublin, Ireland) according to the manufacturer's instructions except using an oligo-dT primer containing a T7 RNA polymerase promoter site. The first round of *in vitro* transcription (IVT) was performed using the MEGAscript T7 kit (Ambion, Warrington, UK). The second round of cDNA preparation was done as first round except now random hexamers replaced the oligo-dT primer.

Labelled cRNA was prepared using the BioArray High Yield RNA Transcript Labeling Kit (Enzo, Farmingdale, NY, USA). Biotin labelled CTP and UTP (Enzo) were used in the reaction together with unlabelled NTPs. During the labelling, the IVT

product and also the fragmented IVT product were checked by gel electrophoresis. Following the IVT reaction, the unincorporated nucleotides were removed using RNeasy columns (Qiagen, Crawley, UK).

Oligonucleotide array hybridisation and scanning

Fragmented cRNA was loaded onto the GeneChip HU133 Plus 2.0 probe array cartridge (Affymetrix). The washing and staining procedure was performed in the Affymetrix Fluidics Station 450 (Affymetrix). The biotinylated cRNA was stained with a streptavidin-PE conjugate, and the probe arrays were scanned at 560 nm using a confocal laser-scanning microscope (Affymetrix Scanner 3000; Affymetrix). After hybridisation and scanning, we checked several quality parameters: scaling factor ≤3-fold difference within a study; 3'/5' ratio for probe sets for GAPDH ≤ 3 ; present (P) calls in the same range for all samples in the study and RawQ below 100. All of our arrays passed all stages of the quality control. The readings from the quantitative scanning were analysed by the Affymetrix Gene Expression Analysis Software (Affymetrix).

Statistical analysis of gene expression data

Affymetrix GeneChip array data were normalised, pre-processed and analysed using R and Bioconductor statistical software (Gentleman et al, 2004). Raw CEL file data from human whole genome Affymetrix U133Plus2 gene GeneChips of purified 'of whole primary' colon cancer samples (n=3) and tumour parenchyma samples purified by FACS (n = 3) were imported into R. Initial exploratory data analysis performed using the overview function in the package made4 (Culhane et al, 2005) suggested that the assumption of a constant sum across all microarray samples may not be valid for these data. Moreover, there were significantly more MAS 5.0 P calls in the whole samples than in the



Figure 2 Fluorescence-activated cell sorting of CRC cells from experimental samples. We generated single cell suspensions from three patient samples and sorted them to greater than 90% purity in each case. Dot plots show the pre- and post-sorting HEA⁺ populations. The table shows the estimates of tumour cell purity in the samples and the initial histological estimates of tumour parenchyma content. We sorted an average of 9 million cells per sample.

9.7

2.7

1.6

FACS-purified samples (paired t-test, P < 0.05). Therefore, data were normalised using the Li and Wong's invariant set method using the 'expresso' function in the Affy package in Bioconductor (Li and Hung Wong, 2001; Gentleman et al, 2004). Normalised data were log2 transformed and assessed initially using use two exploratory data analysis approaches: hierarchical cluster analysis (1-Pearson correlation coefficient distance with average linkage joining) and dimension reduction using correspondence analysis (COA; Eisen et al, 1998; Fellenberg et al, 2001). Figures were created using the made4 package in Bioconductor (Culhane et al, 2005).

Detection of genes differentially expressed in purified tumour

Given the low number of replicates in this study, it is challenging to estimate of gene mean and variance; therefore, rank-based nonparametric methods may be more efficient in these data. It is



Figure 4 Differential gene expression between whole tumour and cellsorted colorectal cancer biopsies. This graph displays the genes called as presented by MAS 5.0 in each sample (P, present; A, absent; M, marginal). There was a significant difference in genes called as present in the wholetissue samples (P = 0.0407, Student's paired t-test). These genes are therefore expressed in non-parenchymal (or stromal) tissue.



Sorted CRC cells from fresh tumour biopsy



MNF-116-stained CRC cells

Figure 3 Cytological confirmation of cell-sorted tumour parenchyma. To confirm that our HEA⁺ CD14⁻ CD45⁻ cell population was tumour parenchyma, we examined three post-sorting populations after cytospinning and Rapi-Diff II (Diagnostic Developments) staining and compared them to SW-480 cells, a cell line derived from a primary colorectal tumour (× 40 magnification shown). Then we confirmed the cells were epithelial by staining with MNF-116 pan-cytokeratin (Dako).

Standard

deviation

17.3

457

reported that rank product performs comparably or outperforms *t*-statistic-based methods when replicates numbers are very low (less than five) (Breitling *et al*, 2004; Jeffery *et al*, 2006). Rank products analysis is a non-parametric statistic that detects genes that are consistently highly ranked in lists, that is genes that are consistently upregulated genes in a number of replicate experiments. Rank products analysis does not require a measure

of gene-specific variance and is therefore particularly powerful when only a small number of replicates are available. Rank products analysis was performed using the Bioconductor package RankProd. False discovery rates were estimated using 100 permutations.

To aid interpretation of these genes lists, we used DAVID to assess which Gene Ontology biological and functional categories



Figure 5 Hierarchical clustering using Eisen's formula of a correlation similarity metric and average linkage clustering led to the cell-sorted samples and whole-tissue samples clustering together, showing they are most similar to each other (**A**). This is despite the fact that they are paired samples. Correspondence analysis also demonstrates that the sorted samples and whole-tissue samples cluster together (**B**). The first axis (horizontal) splits the whole and FACS-purified samples. The second axis (vertical) split E1 and E1W from E6, E12, E12W and E6W. Genes that separate the samples are shown with HUGO classification.

Differential gene expression in CRC parenchyma and stroma MJ Smith et al

were overrepresented in this list of genes (Dennis *et al*, 2003). We used the highest stringency level, for other analyses we used an EASE of 0.01, and false discovery rate of 1000. Heatmap images of gene expression profiles were generated using the made4 package in Bioconductor. The Human Genome Organisation (HUGO) gene symbols for Affymetrix probe sets were retrieved using the annaffy Bioconductor package and the annotation library hu133plus2 (build Tuesday, 4 October 2005, 20:53:27).

RESULTS

Patient demographics and FACS

Three matched patient biopsies were taken immediately after resection. No patients received pre-operative chemoradiotherapy. Metastases (m1) were observed intra-operatively in one patient. The other patients were free from metastases (mx). Histological examination of the E1 and E12 samples demonstrated moderately differentiated adenocarcinomas with strand-like infiltrative pattern of malignant glands through muscularis propria, interspersed by stroma. The E6 sample demonstrated a welldifferentiated adenocarcinoma with closely packed glands invading into muscularis propria, with stroma between the glands. After generation of single cell suspensions from our experimental tumour biopsies, stromal content was estimated to range from 37 to 60%, and sorted to greater than 90% purity as described earlier (Figure 2). The parenchymal component of the tumours was estimated to range from 50 to 80% on histological assessment. The E6 sample demonstrated the biggest discrepancy in estimation of parenchymal content (FC estimate 37 vs 80% histological assessment), which may be explained by the fact that the sample

Table 2 Genes called significant in whole tumour (P<0.01, rank products)

Probe set ID	Gene symbol	Gene title	RP/Rsum	pfp
207961_x_at	МҮНТТ	Myosin, heavy chain 11, smooth muscle	53.331	0
218469_at	GREM I	Gremlin I, cysteine knot superfamily, homolog (Xenopus laevis)	18.3444	0
205594_at	ZNF652	Zinc-finger protein 652	123.6405	0.0011
226663_at	ANKRD I 0	Ankyrin repeat domain 10	122.7271	0.0013
201438_at	COL6A3	Collagen, type VI, α3	113.3836	0.0014
212764_at	ZEBI	Zinc finger E-box-binding homeobox I	139.7127	0.0015
224823 at	MYLK	Myosin light chain kinase	108.5523	0.0017
228030 at	_	Transcribed locus, strongly similar to NP 005768.1 RNA-binding motif protein 6 [Homo sapiens]	38.6 8	0.0017
212077 at	CALD I	Caldesmon I	134.6639	0.0018
206199 at	CEACAM7	Carcinoembryonic antigen-related cell adhesion molecule 7	33.868	0.002
212354 at	SULFI	Sulfatase I	93.7657	0.002
235028 at	_	CDNA FLI42313 fis. clone TRACH2019425	70.702	0.0025
230269 at	_	Transcribed locus	145 6395	0.0029
241879 at	_	Transcribed locus	64 2024	0.0033
227260 at	ANKRDIO	Ankyrin repeat domain 10	201 5746	0.0064
227261_at		CDNA FLI44429 fis clone LITERU2015653	201.37 10	0.0066
2022001_at	Ι ΔΛΛΔ4	laminin #4	207.0227	0.0000
202202_3_at	CREMI	Grantini, Lovetaine knot superfamily, homolog (Xenatus Jaevis)	194 7291	0.0007
238750 at		Transcribed locus	2117612	0.0007
230730_at	(2orfl)	Chromosome 2 open mading frame 12	1834678	0.0007
223207_s_at	C201/12	CDNA ELLIAL fic dopo PLACELO04405	103.4070	0.0000
227140_at	 219	Particles inhibitor 3 clin derived (SALP)	2001148	0.0000
203071_at			10/1202	0.0007
200747_S_al			194.1303	0.007
221740_5_aL		Collegen triple holiv report containing I	103.7447	0.007
223001_dl	CIAKCI	Conagen inperient repeat containing i	213.7720	0.0071
1557270_at			1/1./0/3/	0.0072
202404_s_al		Collagen, type 1, α_2	171.7636	0.0073
223706_al	LUC204702	Pyportetical protein LOC264702	162.3627	0.0075
225664_at	COLIZAI	Collagen, type XII, & I	166.478	0.0075
243134_at		I ranscribed locus	219.3881	0.0075
210809_s_at	POSIN	Penostin, osteoblast-specific factor	188.6781	0.0076
225275_at	EDIL3	EGF-like repeats and discoid in I-like domains 3	1/1.1/1/	0.0076
221729_at	COLSAZ	Collagen, type V, «2	231.1445	0.0086
202948_at	ILIRI	Interleukin I receptor, type I	252.7068	0.0087
225107_at	HNRNPAZBI	Heterogeneous nuclear ribonucleoprotein A2/B1	243.1025	0.0087
226/31_at	PELO	Pelota homolog (Drosophila)	246.3912	0.0087
209656_s_at	IMEM4/	I ransmembrane protein 4/	230.2568	0.0088
218353_at	RGS5	Regulator of G-protein signaling 5	254.393	0.0088
224565_at	TncRNA	Trophoblast-derived noncoding RNA	273.7687	0.0088
212067_s_at	CIR	Complement component I, r subcomponent	241.6854	0.0089
201852_x_at	COL3A I	Collagen, type III, α I (Ehlers-Danlos syndrome type IV, autosomal dominant)	271.8757	0.009
208782_at	FSTLI	Follistatin-like 1	268.8627	0.009
212353_at	SULFI	Sulfatase I	265.4504	0.0091
221778_at	JHDM I D	Jumonji C domain containing histone demethylase I homolog D (S. cerevisiae)	229.742	0.0091
224694_at	ANTXRI	Anthrax toxin receptor I	268.3533	0.0091
225809_at	DKFZP56400823	DKFZP564O0823 protein	261.4881	0.0091
215076_s_at	COL3A I	Collagen, type III, αI (Ehlers-Danlos syndrome type IV, autosomal dominant)	240.3341	0.0092
1555878_at	RPS24	Ribosomal protein S24	260.4235	0.0093
201540_at	FHLI	Four-and-a-half LIM domains I	258.0377	0.0093
231579_s_at	TIMP2	TIMP metallopeptidase inhibitor 2	265.3035	0.0093

contained a large muscularis propria component, which could account for the high proportion of non-staining FC events. Sorted cells were subsequently confirmed as tumour parenchyma by light microscopy assessment (Figure 3). We found the sorted cell population was homogenous and had the morphological appearances consistent with CRC cells after staining with Rapi-Diff and comparison to SW-620 colorectal cell line. The cells also stained positive for the cytokeratin MNF-116, confirming they were epithelial in nature. Using FC we found that the population of HEA $^+$ cells fluoresced in the same region as cells stained with MNF-116.

Differential gene expression

There were significantly more MAS 5.0 P calls in the whole samples than in the FACS-purified samples (paired *t*-test, P < 0.05; Figure 4). Ordination was used to explore the data, and correspondence analysis was applied to the data using the made4 package in Bioconductor (Culhane *et al*, 2005). Correspondence analysis is a useful dimension reduction method for observing the χ^2 or associations between genes and samples. The dendrogram showed that the whole and the purified samples could be portioned into two distinct clusters (Figure 5A). These clusters were also observed on the most variant or first axis of a COA of these data (Fellenberg *et al*, 2001) (Figure 5B). Interestingly, the second most variant axis (F2, vertical) separated the metastatic (E1) and metastatic-free samples. Although we have few replicates in this study, it appeared that metastatic and metastatic-free tumour samples were more defined in the purified samples when compared to the whole samples. The discrimination between metastatic and metastatic-free samples accounted for more variance than difference between tumour stage.

Expression of 289 genes were detected in whole-biopsy samples but not in purified samples (P < 0.05). Of these, 50 differentially expressed genes were highly significant (P < 0.01; Table 2). Expression of 103 genes were detected in purified samples, but significantly downregulated in whole samples (P < 0.05), of which 33 of these were significant at P < 0.01 (Table 3) which are displayed in the Heatmaps in. Heatmaps of the highly significant differentially expressed genes were generated, and displayed in Figure 6.

Functional annotation

We used DAVID to classify gene function in the whole tumour sample (Table 4). Most functional classes are consistent with stromal as opposed to tumour cell function (e.g., protein-aceous extracellular matrix $P = 2.37 \times 10^{-08}$, extracellular matrix $P = 2.49 \times 10^{-08}$, collagen triple helix repeat $P = 7.12 \times 10^{-07}$), although genes known to be expressed in tumour epithelium were identified (e.g., *GREM1*). Looking at individual genes, upregulation of connective tissue genes was prevalent (e.g., *COL6A3, COL1A2, COL12A1, COL5A2, COL3A1, CTHRC1, SULF1*), as were genes involved in extracellular matrix function (e.g., *LAMA4, PI3, POSTN, TIMP2*) and cell adhesion (e.g., *TNS1*). Genes involved in endothelial function (e.g., *TIMP2*) and specifically, colon cancer tumour endothelium, such as the anthrax toxin receptor (*ANTXR1*), were also upregulated (Liu *et al*, 2008).

Table 3 Genes called significant in FACS purified CRC cells (P < 0.01, rank products)

Probe set ID	Gene symbol	Gene title	RP/Rsum	pfp
200664 s at	DNAIBI	Dnal (Hsp40) homolog, subfamily B, member I	68.0709	0
204018_x_at	HBAI	Haemoglobin, al	66.0374	0
209116 x at	HBB	Haemoglobin, β	10.5524	0
209458_x_at	HBA I	Haemoglobin, al	60.4785	0
211699_x_at	HBA I	Haemoglobin, αΙ	67.0989	0
211745 x at	HBA I	Haemoglobin, al	52.9371	0
214414 x at	HBA I	Haemoglobin, al	61.1365	0
217232 x at	HBB	Haemoglobin, β	8.1213	0
217316 at	OR7A10	Olfactory receptor, family 7, subfamily A, member 10	59.4448	0
217414 x at	HBA I	Hemoglobin, al	28.7839	0
225762_x_at	LOC284801	Hypothetical protein LOC284801	9.059	0
225767_at	_		42.7413	0
229667_s_at	HOXB8	Homeobox B8	34.4176	0
204419_x_at	HBGI	Haemoglobin, γA	97.798	0.0012
1565817 at	IKZFI	IKAROS family zinc-finger 1 (Ikaros)	93.4767	0.0013
211696 x at	HBB	Haemoglobin, β	92.8953	0.0013
209795 at	CD69	CD69 molecule	92.588	0.0014
231100 at	RRAD	Ras-related associated with diabetes	135.6185	0.0044
207574 s at	GADD45B	Growth arrest and DNA-damage-inducible, β	152.1069	0.0052
208252 s at	CHST3	Carbohydrate (chondroitin 6) sulfotransferase 3	149.7873	0.0052
212099 at	RHOB	Ras homolog gene family, member B	151.4472	0.0055
225377_at	C9orf86	Chromosome 9 open-reading frame 86	145.8861	0.0055
230935_at			144.722	0.0058
243001_at	C18orf22	Chromosome 18 open-reading frame 22	167.4874	0.006
202768_at	FOSB	FBI murine osteosarcoma viral oncogene homolog B	163.3693	0.0062
210042_s_at	CTSZ	Cathepsin Z	174.6238	0.0062
1569428_at	WIBG	Within bgcn homolog (Drosophila)	190.2299	0.0071
206834 at	HBB	Haemoglobin, β	203.1012	0.0073
1556262_at	_	CDNA clone IMAGE:4822139	208.8925	0.0074
220369 at	SMEKI	SMEK homolog 1, suppressor of mek1 (Dictyostelium)	189.2357	0.0074
244804 at	SOSTMI	Sequestosome I	210.7027	0.0075
235102_x_at		Transcribed locus	199.6653	0.0076
2 35 5_x_at	HBGI	Haemoglobin, yA	223.858	0.0088
237518_at	—	Transcribed locus	225.91	0.0091

Differential gene expression in CRC parenchyma and stroma MJ Smith et *al*

In contrast, the 31 highly significantly expressed genes in the FACS-purified cells do not display characteristics of stromal gene expression, and may be representative of tumour parenchyma gene expression. Genes involved in cell signalling, such as *SQSTM1*, which regulates activation of the nuclear factor- κ B (NF- κ B) signalling pathway, receptor internalisation, and protein turnover, and *RRAD*, a member of the Ras/GTPase superfamily, are also overexpressed (Moyers *et al*, 1997; Seibenhener *et al*, 2007). Genes known to be expressed in CRC were also significantly upregulated, such as *HOX2D* and *RHOB*, which mediate apoptosis in neoplastic cells, and are targets for novel antitumour agents, such as farnesyltransferase inhibitors (Vider *et al*, 1997; Delarue *et al*, 2007).

Comparison with Kwong et al expression signature

Kwong *et al* (2005) examined the expression signature derived from 60 tumours (normal mucosa, adenoma, tumour and liver metastases) and identified an expression profile that was able to differentiate between normal and neoplastic samples, but not individual tumour stages. They suggested that stromal genes may obscure the subtle molecular changes in tumours of differing pathological stage. Examination of their gene list, specifically the 34 upregulated genes in their signature, reveals the expression of extracellular matrix proteins such as, collagen, type I, $\alpha 1$ (*COL1A1*) and fibronectin. The authors believe this represented gene expression derived from infiltrating lymphocytes and other stroma. The gene list they identified shares similarities to gene expressed in our whole tumour sample (*ANTXR1*, *COL12A1*, *COL5A2*, *CTHRC1*, *POSTN*).

DISCUSSION

Our study demonstrates that it is feasible to reproducibly separate and purify tumour parenchyma and other cell populations from a single cell suspension generated from a solid tumour using FACS. We also found that the gene expression profile elicited from the whole tumour was significantly different from that of the purified tumour parenchyma, and that source of this differential expression may be tumour stroma. When tumour parenchymal purity is necessary, FACS may be an alternative to LCM, in particular in tumours such as CRC, melanoma and other nonsclerotic tumours amenable to the generation of a single cell suspension.

In our samples, we noted a large variance in estimated quantity of tumour parenchyma and stroma. Using FC we estimated that the parenchymal component of the tumours ranged from 37 to



Figure 6 Genes detected by rank products analysis (P < 0.01). Heatmaps showing the differentially expressed genes detected in whole but not purified samples (**A**) and purified but not whole samples (**B**) using rank product analysis (P < 0.01) using Z-score normalised values (row centred). Red tiles represent upregulated genes and blue represent downregulated genes.



Figure 6 Continued

60% and stroma from 40 to 63%. This was enriched to over 90% (range 90-96%) in each case with one sorting run per sample after calibration of the machine and settings for each sample. Verification of cell type is straightforward with standard staining techniques. We believe this level of stroma would grossly affect the gene expression profile taken from the biopsy and would be in keeping with the findings of Sugiyama *et al* (2002).

For publication we specifically used rank products as this has been shown to be reliable in small sample sizes in microarray experiments (Breitling *et al*, 2004; Jeffery *et al*, 2006). We found that the expression profile in the whole elicited also made biological sense. We are confident that there are real differences in the gene identified, which are related to the stromal gene expression, and that this has implications for clinical application of gene expression microarrays in CRC.

The MammaPrint assay, which is a clinical application of the van't Veer 70-gene breast cancer expression profile, relies on a single fresh sample of tumour to predict prognosis (van 't Veer *et al*, 2002; Cardoso *et al*, 2008). The samples are examined, and a stromal content of <50% is deemed acceptable for the test. This would arguably eliminate two of our samples from analysis, which we were able to enrich to >90% purity. However, Wang *et al* (2004), who derived an expression profile predicting recurrence of Duke's B colorectal carcinoma, included only samples that were

enriched to over 85% purity. We believe that in CRC samples, the stroma will contaminate the sample causing problems with patient classification, but that can be overcome with parenchymal purification. The optimal tumour/stroma ratio for gene expression studies is yet to be determined and may vary depending on the tumour type.

To ensure good quality expression data, we used several layers of quality control, starting with RNA gel electrophoresis and then checking RNA integrity with the Agilent Bioanalyzer (Agilent). Subsequently, after hybridisation and scanning, we checked several quality parameters such as scaling factor, 3'/5' ratios, P calls and RawQ values. Quantitative RT-PCR was not employed as all of our arrays passed all stages of the quality control, and we do not believe that it will be used in clinical practice. This has been borne out by the current application of the MammaPrint assay and is a similar approach to other clinical microarray studies (Wang *et al*, 2004; Glas *et al*, 2006; Ach *et al*, 2007; Cardoso *et al*, 2008).

We found a significant difference in the total number of probes called as present using the Affymetrix MAS5 signal algorithm. This shows that the whole tissue expressed a larger number of genes than sorted cells, demonstrating the wide range of genes expressed by non-tumour cells. We used Li and Wong's invariant set method for normalisation of the data sets (Li and Hung Wong, 2001). This

1462

Category

Differential gene expression in CRC parenchyma and stroma

Term

MJ Smith et al

Gene count

Percentage

P-value

Table 4 Functional classification of whole tumour gene expression with DAVID (top 50)

	51_111
	GO_CC
	UP SEO
	JI _I IIX
	INTERPRO
	SP_PIR
	SP PIR
	SP PIR
	GO_BP
	SP_PIR
	GO_CC
	SP PIR
	SP PIR
	SF_FIR
	SP_PIR
	INTERPRO
	GO BP
	GOBP
	GO_III
	KEGG
	UP_SEQ
	PIR_SUPERFAMILY
	KEGG
	SP PIR
	GO_BP
	GO_MF
	UP_SEQ
	SP PIR
_	GO BP
<u> </u>	
<u> </u>	GO_BF
$\overline{0}$	GO_CC
0	INTERPRO
	KEGG
2	go bp
	GO BP
—	UP_SEQ
2	SIMARI
4	UP_SEQ
6	GO_BP
Š.	UP SEO
₫.	GOBP
0	
0	
	GO_BP

CQ_CC Extracellular region 17 34.96 6.316–10 SQ_CC Profenaceous extracellular matrix 10 21.74 2.376–09 SQ_CC Extracellular matrix 9 9.57 2.476 SQ_CC Extracellular matrix 9 9.57 2.476 SQ_CC Extracellular matrix 10 2.1.74 2.716 SQ_CC Extracellular matrix part 7 1.5.22 1.008–07 SQ_FCC Extracellular matrix part 7 1.5.22 1.008–07 SQ_FRC Signal peptide 22 47.83 1.487–07 PLR Transer 5 1.081 3.615–07 PLPR Transer 5 1.087 7.352–07 PLPR Hydroxymoline 5 1.087 7.352–07 SQ_PR Hydroxymoline 5 1.087 7.452–07 SQ_PR Hydroxymoline 5 1.087 7.452–07 SQ_PR Hydroxymoline 5 1.087 7.052–07	GO_CC	Extracellular region part	15	32.61%	3.87E-10
PP_RR Hydrosylation 7 15.22 5.82E-09 PD_RK Extracellular matrix 0 21.74 2.27E-08 PD_RK Extracellular matrix 0 21.74 2.27E-08 PD_RK Signal 22 4.783 3.38E-08 PLPRK Signal peptide 22 4.783 3.38E-08 PLPRK Signal peptide 22 4.783 3.38E-08 PLPRK Triple helix repeat 5 10.057 7.53E-07 PLPRK Triple helix repeat 5 10.057 7.53E-07 PLPRK Triple helix repeat 5 10.057 7.53E-07 PLPRK Triple helix repeat 5 10.07 7.23E-07 Store CC Collagen 5 10.07 1.07E-06 PLPRK Hydrosynore 5 10.07 1.07E-06 PLPRK Hydrosynore 5 10.07 1.07E-06 PLPRK Hydrosynore 5 10.07 3.16E-06 PLPRK	GO_CC	Extracellular region	17	36.96	6.31E-10
SD_CC Proteinaccous extracellular matrix 10 2.174 2.37E-08 SD_CC Extracellular matrix 10 2.174 2.176 SD_CC Extracellular matrix 10 2.174 2.176 SD_CC Extracellular matrix part 7 1.522 1.006-07 SD_PSC Signal peptide 22 4.783 3.88E-08 SD_CC Extracellular matrix part 7 1.522 1.006-07 PLRK Trinter 5 1.037 3.41E-07 PLRK Triple helix repeat 6 1.304 2.12E-07 PLRK Triple helix repeat 5 1.037 2.33E-07 PLRK Triple helix repeat 5 1.037 2.42E-07 SD_DCC Collagen 5 1.037 1.04E-06 SD_CCC Collagen 5 1.037 1.04E-06 SD_PR Plot constructure 5 1.037 7.04E-06 SD_RP Organic anion transport 6 1.304 1.22E-07 <td>SP_PIR</td> <td>Hydroxylation</td> <td>7</td> <td>15.22</td> <td>5.82E-09</td>	SP_PIR	Hydroxylation	7	15.22	5.82E-09
PJPR Extracellular matrix 9 19.57 29.48-08 SQ_CC Extracellular matrix part 1 2.174 2.216.08 PJPR Signal paptide 22 47.83 3.868-08 PJPR Timer 5 10.87 3.461-07 PJPR Timer 5 10.87 3.461-07 PJPR Timer 5 10.87 4.864-07 PJPR Hydroxysine 5 10.87 7.838-07 PJPR Hydroxysine 5 10.87 8.664-07 PJPR Hydroxysine 5 10.87 1.228-06 Socrected 5 10.87 1.228-06 0.272 Sold Reg Collagen 5 10.87 1.228-06 PJPR Direct protein sequencing 18 31.13 2.488-06 PJPR Direct protein sequencing 18 31.13 2.488-06 PJPR Direct protein sequencing 18 13.04 1.247-06 SOLAR Structural pr	GO_CC	Proteinaceous extracellular matrix	10	21.74	2.37E-08
SO_CC Extracellular matrix part 10 21,74 27,74 SP,PR Signal 2 47,83 38,88-08 SO_CC Extracellular matrix part 7 15,22 1,000-07 P,PR Timer 7 15,22 1,000-07 P,PR Timer 5 10,87 3,816-07 P,PR Timer 5 10,87 3,836-07 P,PR Tiple helix repeat 6 13,04 47,125-07 P,PR Tiple helix repeat 15 3,26 10,87 10,62 P,PR Prophate transport 6 13,04 9,77E 07 P,PR Hydroxypoine 5 10,87 11,05-06 0,97 P,PR Collagen 6 13,04 12,47-06 0,97 P,PR Collagen 6 13,04 12,47-06 0,97 P,PR Collagen 6 13,04 12,47-06 0,97 P,PR Collagen 6 13,04	SP_PIR	Extracellular matrix	9	19.57	2.49E-08
Pi,PiR Signal 22 47.83 388E-06 SO_CC EvaceIlular matrix part 7 15.22 1.006-07 P.P.PIR Timer 2 47.83 1.49F-07 P.P.PIR Timer 5 1.037 3.41E-07 NTERPRO Collagen triple heix repeat 6 1.304 7.12E-07 P.P.PIR Hydroxysine 5 1.087 4.862E-07 P.P.PIR Hydroxysine 5 1.087 4.862E-07 SD_P Phosphate transport 6 1.304 9.47E-07 SD_P.P.R Hydroxyspine 5 1.087 1.02E-06 SD_CCC Collagen 5 1.087 1.22E-06 SD_P.P.R Direct protein sequencing 18 39.13 2.48E-06 SP.P.R Direct protein sequencing 18 39.13 2.48E-06 SP.P.R Direct protein sequencing 18 39.13 2.48E-06 SP.P.R Direct protein sequencing 18 30.13 2.48E-06	GO_CC	Extracellular matrix	10	21.74	2.71E-08
SD_CC Extracellular matrix part 7 15.22 (100E-07) PJRN Trimer 5 10.87 3.41E-07 PJRN Trimer 5 10.87 3.41E-07 PJRN Triple helix repeat 6 13.04 7.1ZE-07 PJRN Triple helix repeat 5 10.87 7.53E-07 PJRN Screted 15 3.261 8.67E-07 PJRN Screted 15 3.261 8.67E-07 PJRN Nodphate transport 6 13.04 9.77E-07 PJRN Olagen 6 13.04 9.72E-06 PJRN Collagen 6 13.04 1.24E-06 PJRN Direct protein sequencing 18 3.913 2.48E-06 PJRN Proglutaria acid 5 10.87 7.04E-06 PJRN Proglutaria 6 13.04 4.91E-06 PJRN Proglutaria 5 10.87 7.04E-06 SO_BP Anion transport	SP_PIR	Signal	22	47.83	3.88E-08
JP_SEQ Signal periode 22 47.83 1.49E-07 JP_RR Trimer 5 10.87 3.61E-07 NTERPRO Collagen triple heik repeat 6 13.04 7.12E-07 JP_RR Hydroxylyine 5 10.87 7.33E-07 JP_RR Hydroxylyine 5 10.87 8.60E-07 JP_RR Hydroxylyine 5 10.87 8.60E-07 JO_PR Phosphate transport 6 13.04 9.47E-05 JO_PR Phosphate transport 6 13.04 1.02E-06 JP_PR Direct protein sequencing 18 39.13 2.24E-06 JP_PR Direct protein sequencing 18 39.13 2.44E-06 JP_PR Direct protein sequencing 6 13.04 1.22E-06 JP_PR Direct protein sequencing 18 19.13 2.44E-06 JP_PR Non transport 6 13.04 1.22E-06 JO_PR Organ canion transport 6 13.04 1.74E-05	GO_CC	Extracellular matrix part	7	15.22	1.00E-07
PJRR Timer 5 10.87 3.61E-07 PJ.PIR Triple helix repeat 6 13.04 7.12E-07 PJ.PIR Triple helix repeat 5 10.87 7.33E-07 PJ.PIR Serveted 15 3.261 8.60E-07 PJ.PIR Serveted 15 3.261 8.60E-07 SD_SP Prophate transport 6 13.04 9.77E-07 SD_SP Prophate transport 5 10.87 1.02E-06 SD_CC Collagen 5 10.87 1.24E-06 SP.PR Direct protein sequencing 18 3.913 2.48E-06 SP.PR Direct protein sequencing 18 3.04 1.24E-06 SD_PP Anone transport 6 13.04 6.91E-06 SD_PP Anone transport 6 13.04 1.37E-06 SO_BP Anone transport 6 13.04 1.37E-06 SO_BP Anone transport 5 10.87 7.67E-05 SP.SRA	JP_SEQ	Signal peptide	22	47.83	I.49E-07
NIERPRO Collagen truje heik repeat 6 13.04 7.12E-07 PJ.PR Hydroxylysine 5 10.87 7.53E-07 PJ.PR Hydroxylysine 5 10.87 8.60E-07 SO_BP Phosphate transport 6 13.04 8.60E-07 SO_BP Phosphate transport 6 13.04 9.47E-07 SO_BP Phosphate transport 6 13.04 1.12E-06 SO_PR Collagen 5 10.87 1.22E-06 PLPR Orlagen insquencing 18 3.913 2.48E-06 PLPR Proglutamic acid 5 10.87 3.81E-06 SUPP Organic anon transport 6 13.04 4.91E-06 SO_BP Anion transport 5 10.87 7.04E-05 SO_BP Anion transport 5 10.87 7.91E-05 SO_BP Anion transport 5 10.87 7.92E-07 SO_DMF Extracellular matrix structural constituent 5 10.87 7.92E-04	SP_PIR	Trimer	5	10.87	3.61E-07
P.P.R. Triple helix 5 10.87 2.53E-07 P.P.R. Secreted 15 32.61 8.62E-07 P.P.R. Secreted 15 32.61 8.62E-07 P.P.R. Phyophate transport 6 13.04 9.47E-07 P.P.R. Hydroxylysine 5 10.87 1.10E-06 SO_CC Collagen 5 10.87 1.22E-06 SP.P.R Orlagen is sequencing 18 39.13 2.48E-06 SP.P.R Syncural protein 6 13.04 1.24E-05 SP.P.R Droganic anion transport 6 13.04 1.72E-05 SO_BP Origanic anion transport 6 13.04 1.72E-05 SO_BP Origanic anion transport 5 10.87 7.64E-05 SO_BP Origanic anion transport 5 10.87 7.64E-05 SO_BP Origanic transity structural constituent 5 10.87 7.64E-05 SO_BR EdGG ECFAreceptori interaction 5	NTERPRO	Collagen triple helix repeat	6	13.04	7.12E-07
P.P.R. Hydroxypsine 5 10.87 8.60E-07 JSP.R. Secreted 15 32.61 8.62E-07 JSD_PP Phosphate transport 6 13.04 9.47E-07 JSD_RR Hydroxyproline 5 10.87 1.12E-06 JSD_CCC Collagen 6 13.04 1.24E-06 JP.R Direct protein sequencing 18 39.13 2.44E-06 JSP_RR Direct protein sequencing 18 39.13 2.44E-06 JP.R Direct protein report 6 13.04 1.61E-06 JSP_R Direct protein report 6 13.04 1.73E-05 JSD_BP Organic anion transport 6 13.04 1.73E-05 JSD_MF Extracellular matrix structural constituent 5 10.87 7.67E-05 SGCG FORL sequencinc motificel latachment site 5 10.87 7.67E-05 SGCG FORL abelon 6 13.04 1.39E-04 JP.FR Olysperotein 12 2.26 <td>SP_PIR</td> <td>Triple helix</td> <td>5</td> <td>10.87</td> <td>7.53E-07</td>	SP_PIR	Triple helix	5	10.87	7.53E-07
PJ.PIR Secretal 15 32.61 6.621–07 D2.PB Phosphate transport 6 13.04 P.47E–07 PJ.PIR Hydroxyproline 5 10.87 1.102–06 D.P.PIR Collagen 5 10.87 1.122–06 P.PIR Direct protein sequencing 18 39.13 2.48E–06 P.P.R Direct protein sequencing 18 39.13 2.48E–06 P.P.R Structural protein 6 13.04 6.91E–06 D.P.P.R Structural protein 6 13.04 6.91E–06 SO_BP Organic anion transport 6 13.04 1.73E–05 SO_BP Organic nainon transport 6 13.04 1.73E–05 SO_MF Extracellular matrix structural constituent 5 10.87 7.67E–05 SO_MF Extracellular matrix structural constituent 3 6.52 9.79F–05 SUPERFAMILY Colagen at/10 chain 3 6.52 9.79F–05 GLGG Foclal athesion 13 </td <td>SP_PIR</td> <td>Hydroxylysine</td> <td>5</td> <td>10.87</td> <td>8.60E-07</td>	SP_PIR	Hydroxylysine	5	10.87	8.60E-07
3D_BP Phosphate transport 6 1304 947E-07 SP_PR Hydroxynorine 5 1087 1.08E-06 SQ_CC Collagen 5 1087 1.22E-06 SP_PR Direct protein sequencing 18 39.13 2.24E-06 SP_PR Pyroglutamic acid 5 10.87 3.81E-06 SP_PR Direct protein 6 13.04 0.91E-05 SO_DP Organic acino transport 6 13.04 3.99E-05 SO_DP Anion transport 6 13.04 3.99E-05 SO_DMF Extracellular matrix structural constituent 5 10.87 7.67E-05 SO_DMF Extracellular matrix structural constituent 5 10.87 9.21E-05 SO_DMF Collagen 1(0, chain 3 652 9.79E-05 SO_SOF Focal adhesion 6 13.04 1.39E-04 SP_PR System development 13 28.26 1.62E-04 SO_MF System development 13 28.26 <td>SP_PIR</td> <td>Secreted</td> <td>15</td> <td>32.61</td> <td>8.62E-07</td>	SP_PIR	Secreted	15	32.61	8.62E-07
PJ.PIR Hydroxyproline 5 10.87 1.10E-06 SQ_CC Collagen 5 10.87 1.22E-06 SP_PIR Collagen 6 13.04 1.24E-06 SP_PIR Direct protein sequencing 18 39.13 2.44E-06 SP_PIR Proglutamic acid 5 10.87 2.44E-06 SP_PIR Structural protein 6 13.04 6.91E-06 SO_BP Organic anion transport 6 13.04 1.73E-05 SO_BP Anion transport 6 13.04 1.73E-05 SO_MF Extracellular matrix structural constituent 5 10.87 7.67E-05 SGG CEM-receptor interaction 3 6.52 9.79E-04 SP_RN Glogan et III (h chain 3 6.52 9.79E-04 SO_LPR System development 13 2.826 1.62E-04 SO_MPR System development 13 2.826 1.62E-04 SO_SPP Organ development 13 2.822 <td< td=""><td>GO_BP</td><td>Phosphate transport</td><td>6</td><td>13.04</td><td>9.47E-07</td></td<>	GO_BP	Phosphate transport	6	13.04	9.47E-07
CGC Collagen 5 10.87 1.22E-06 PF,PIR Collagen 6 13.04 1.24E-06 PF,PIR Direct protein sequencing 18 39.13 2.248E-06 PF,PIR Diructural protein 6 13.04 6.91E-06 PF,PR Structural protein 6 13.04 6.91E-06 NTERPRO Collagen heix repeat 5 10.87 7.04E-06 SO_BP Anion transport 6 13.04 1.73E-05 SO_MF Extracellular matrix structural constituent 5 10.87 7.67E-05 SO_ME ECM-receptor interaction 5 10.87 7.67E-05 RS/UERFAMILY Colagen at (f) chain 3 6.52 9.79E-06 CEG Forcat adhesion 6 13.04 1.39E-04 SO_BP System development 13 28.26 1.62E-04 SO_BP System development 13 28.26 1.83E-04 SO_DAF System development 14 2.30	SP_PIR	Hydroxyproline	5	10.87	1.10E-06
PJPIR Collagen 6 13.04 1.24E-06 PP, PR Direct protein sequencing 18 39.13 248E-06 SP, PR Proglutanic acid 5 10.87 3.81E-06 SP, PR Structural protein 6 13.04 6.91E-06 SO_SP Organic anion transport 6 13.04 1.73E-05 SO_SP Anion transport 6 13.04 3.99E-05 SO_MF Extracellular matrix structural constituent 5 10.87 7.67E-05 SO_MF Extracellular matrix structural constituent 5 10.87 7.67E-05 SP_SEQ Short sequence motif.Cell attachment site 5 10.87 7.67E-05 SP_SEQ Short sequence motif.Cell attachment site 5 10.87 9.21E-05 SP_SEQ Short sequence motif.Cell attachment site 5 10.87 9.21E-05 SP_SEQ Short sequence motif.Cell attachment site 3 6.52 1.83E-04 SD_SP System development 13 2.826 1.62E-04	GO_CC	Collagen	5	10.87	1.22E-06
PJP,R Direct protein sequencing 18 39,13 2.48E-06 P,PR Pyroglutamic acid 5 10.87 3.81E-06 P,PR Structural protein 6 13.04 6.91E-06 SD_PP Organic anion transport 6 13.04 1.73E-05 SO_BP Anion transport 6 13.04 1.73E-05 SO_MF Extracellatin arbits structural constituent 5 10.87 6.54E-05 CEGG ECM-receptor interaction 5 10.87 7.67E-05 SP_SEQ Short sequence motif-Cell atachment site 5 10.87 7.67E-05 SP_SEQ Forcal arbision 6 13.04 1.39E-04 SO_MF Structural noceum activity 9 1.95T 1.68E-04 SP_PR Organ al (I) chain 13 2.826 1.82E-04 SO_MF Structural noceum activity 9 1.95T 1.68E-04 MP_PR Propeptide-Cterminal propeptide 3 6.52 1.82E-04 SO_MF Drata cellar ma	SP_PIR	Collagen	6	13.04	1.24E-06
PJP.IR Pyrogutamic acid 5 10.87 3.81E-06 SP. PR Structural protein 6 13.04 6.91E-06 NTERPRO Collagen heix repeat 5 10.87 7.04E-06 SO_BP Organic anion transport 6 13.04 1.73E-05 SO_MF Extracellular matrix structural constituent 5 10.87 7.67E-05 SG.MF Extracellular matrix structural constituent 5 10.87 7.67E-05 RSJVERFAMILY Collagen al (I) chain 3 6.52 9.79E-05 RSGG Focal adhesion 6 13.04 1.39E-04 P.P.R Glycoprotein 19 41.30 1.57E-04 SO_MF Structural molecule activity 9 19.57 1.68E-04 SO_MF Structural molecule activity 9 19.57 1.68E-04 SO_MF Structural molecule activity 9 19.57 1.68E-04 SO_BP System development 11 23.91 2.43E-04 SO_DEP Extracellula	SP_PIR	Direct protein sequencing	18	39.13	2.48E-06
ip-IPR Surdural protein 6 13.04 6.91E-06 NTERPRO Collagen heix repeat 5 10.87 7.04E-06 SO_SP Organic anion transport 6 13.04 1.73E-05 SO_SP Anion transport 6 13.04 1.73E-05 SO_SP Anion transport 6 13.04 3.97E-05 SO_MF Extracellar matrix structural constituent 5 10.87 7.67E-05 SIR_SUPERFAMILY Collagen x1(1) chain 3 6.52 9.79E-05 SIR_SUPERFAMILY Collagen x1(1) chain 13 2.826 1.63E-04 SO_MF Structural molecule activity 9 19.57 1.68E-04 SO_MF Structural molecule activity 9 19.57 1.68E-04 JP_SEQ Properptide:C-terminal properptide 3 6.52 1.88E-04 SO_SP Extra ellular matrix organization and biogenesis 4 8.70 2.45E-04 SO_SP Extra ellular matrix organization and biogenesis 4 8.70 2.45E-04	SP_PIR	Pyroglutamic acid	5	10.87	3.81E-06
NTERRO Colagen relix repeat 5 10.87 7.04E-06 GO_BP Organic anion transport 6 13.04 1.73E-05 GO_MF Extracellular matrix structural constituent 5 10.87 6.54E-05 GG ECM-receptor interaction 5 10.87 7.67E-05 JP_SEQ Short sequence motif.Cell attachment site 5 10.87 7.67E-05 GIR_SUPERFAMILY Collagen xl (I) chain 3 6.52 9.79E-05 EGG Focal adhesion 6 13.04 1.37E-04 GO_BP System development 13 28.26 1.62E-04 GO_PR System development 3 6.52 1.88E-04 JP_PIR Ehlers-Danios syndrome 3 6.52 1.88E-04 GO_BP Organ development 1 23.91 2.48E-04 GO_DP Organ development 3 6.52 1.88E-04 GO_CC Fibrillar collagen. C-terminal 11 23.91 2.48E-04 GO_DP Organ development. <td>SP_PIR</td> <td>Structural protein</td> <td>6</td> <td>13.04</td> <td>6.91E-06</td>	SP_PIR	Structural protein	6	13.04	6.91E-06
SO_BP Organic anion transport 6 13.04 1.73E-05 SO_BP Anion transport 6 13.04 3.99E-05 SO_MF Extracellular matrix structural constituent 5 10.87 7.67E-05 P_SEQ Short sequence motifical attachment site 5 10.87 7.67E-05 P_SEQ Short sequence motifical attachment site 5 10.87 7.67E-05 PR_SUPERFAMILY Collagen at (I) chain 3 6.52 9.79E-05 GG Focal adhesion 6 13.04 1.39E-04 P_PIR Glycoprotein 19 41.30 1.77E-04 SO_MF Structural molecule activity 9 1.957 1.68E-04 SO_MP Organ development 11 2.391 2.43E-04 SO_BP Organ development 11 2.391 2.43E-04 SO_CC Fibrillar collagen 3 6.52 2.71E-04 SO_CC Fibrillar collagen 3 6.52 2.74E-04 SO_CC Fibrillar collagen	NTERPRO	Collagen helix repeat	5	10.87	7.04E-06
GO BP Arion transport 6 13.04 399E-05 GO MF Extracellular matrix structural constituent 5 10.87 6.54E-05 GO MF ECM-receptor interaction 5 10.87 7.67E-05 JP_SEQ Short sequence motif-Cell attachment site 5 10.87 9.21E-05 RS_UPERFAMILY Collagen at I(I) chain 3 6.52 9.79E-05 GEG Focal adhesion 6 13.04 1.39E-04 JP_PR Glycoprotein 19 41.30 1.57E-04 GO_BP System development 13 28.26 1.68E-04 JP_SEQ Propeptide-C-terminal propeptide 3 6.52 1.88E-04 JP_PR Enlers-Danlos syndrome 3 6.52 1.88E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_BP Childra matrix organization and biogenesis 4 8.70 2.48E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.71E-04 GO_BP <td< td=""><td>GO BP</td><td>Organic anion transport</td><td>6</td><td>13.04</td><td>1.73E-05</td></td<>	GO BP	Organic anion transport	6	13.04	1.73E-05
GO_MF Extracellular matrix structural constituent 5 10.87 654E-05 EEGG ECM-receptor interaction 5 10.87 7.67E-05 P_SEQ Short sequence motificall attachment site 5 10.87 9.21E-05 R_SUPERFAMILY Collagen zl (I) chain 3 6.52 9.77E-05 GC_BR Focal adhesion 6 13.04 1.39E-04 G_PLPR Glycoprotein 19 41.30 1.57E-04 GO_MF Structural molecule activity 9 19.57 1.68E-04 JP_SEQ PropeptideC-terminal propeptide 3 6.52 1.88E-04 GO_BP Structural molecule activity 9 19.57 1.88E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.43E-04 GO_DSP Extracellular matrix organization and biogenesis 4 8.70 2.43E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.71E-04 NTERPRO Hibrillar collagen, C-terminal 3 6.52	GO BP	Anion transport	6	13.04	3.99E-05
KECG ECM-receptor interaction 5 10.87 7.67E-05 JP_SEQ Short sequence motif-Cell attachment site 5 10.87 9.21E-05 RS_UPERRAMILY Collagen at (1) chain 3 6.52 9.79E-05 KEGG Focal adhesion 6 13.04 1.39E-04 GD_BP System development 13 28.26 1.62E-04 GO_MF Structural molecule activity 9 19.57 1.68E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.84E-04 GO_BP Multicellular organismal development 14 3.043 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 GO_BP Multicellular organismal process 17 36.96 6.31E-04 GO_BP <	GO MF	Extracellular matrix structural constituent	5	10.87	6.54E-05
JP_SEQ Short sequence motif.Cell attachment site 5 10.87 921E-05 NR_SUPERFAMILY Collagen &(10) chain 3 6.52 9.79E-05 SR_SUPERFAMILY Collagen &(10) chain 6 13.04 1.37E-04 SP_PIR Glycoprotein 19 41.30 1.57E-04 GO_BP System development 13 28.26 1.62E-04 GO_MF Structural molecule activity 9 19.57 1.68E-04 JP_SEQ Propeptide-C-terminal propeptide 3 6.52 1.88E-04 GO_BP Organ development 11 2.391 2.43E-04 GO_BP Drigan development 11 2.391 2.43E-04 GO_BP Ethacslular matrix organization and biogenesis 4 8.70 2.42E-04 GO_BC Cell communication 5 10.87 4.06E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 GO_BP Multicellular organismal process 17 36.92 0.0160202 G	KEGG	ECM-receptor interaction	5	10.87	7.67E-05
PR_SUPERFAMILY Collagen x1(1) chain 3 6.52 9.79E-05 EEGG Focal adhesion 6 13.04 1.39E-04 SUPERFAMILY Glycoprotein 19 41.30 1.57E-04 GO_BP System development 13 28.26 1.62E-04 GO_MF Structural molecule activity 9 19.57 1.68E-04 JP_SEQ Propeptide-C-terminal propeptide 3 6.52 1.83E-04 GO_BP Chran development 11 2.391 2.43E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.43E-04 GO_CC Fibrillar collagen 3 6.52 2.71E-04 NTERPRO Fibrillar collagen, C-terminal 3 6.52 2.04E-04 GO_BP Muticellular organismal process 17 3.66 6.33E-04 GO_BP Muticellular organismal process 17 3.652 7.14E-04 GO_BP Muticellular organismal process 13 2.826 0.0001069024 GJ_PSCQ	JP SEO	Short sequence motif:Cell attachment site	5	10.87	9.21E-05
KEGG Focal adhesion 6 13.04 1.39E-04 VP_PIR Glycoprotein 19 41.30 1.57E-04 GO_BP System development 13 28.26 1.62E-04 GO_MF Structural molecule activity 9 19.57 1.68E-04 JP_SEQ PropeptideC-terminal propeptide 3 6.52 1.83E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_CC Fibrillar collagen 3 6.52 2.71E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.71E-04 NTERPRO Fibrillar collagen, C-terminal 3 6.52 2.71E-04 SO_BP Multicellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 JP_SEQ Domain/VVFC 3	PIR SUPERFAMILY	Collagen $\alpha (l)$ chain	3	6.52	9.79E-05
SP_PR Glycoprotein 19 41.30 1.57E-04 GO_BP System development 13 28.26 1.62E-04 GO_MF Structural molecule activity 9 19.57 1.68E-04 JP_SEQ PropeptideC-terminal propeptide 3 6.52 1.83E-04 JP_PR Ehlers-Danlos syndrome 3 6.52 1.83E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.71E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.44E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 JP_SEQ Domain/WFC 3 <td< td=""><td>KEGG</td><td>Focal adhesion</td><td>6</td><td>13.04</td><td>1.39E-04</td></td<>	KEGG	Focal adhesion	6	13.04	1.39E-04
Solution System development 13 28.26 1.62E-04 GO_MF Structural molecule activity 9 19.57 1.68E-04 JP_SEQ Propeptide:C-terminal propeptide 3 6.52 1.83E-04 JP_SEQ Propeptide:C-terminal propeptide 3 6.52 1.83E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_CC Fibrillar collagen 3 6.52 2.71E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.45E-04 GO_CC Fibrillar collagen 3 6.52 2.71E-04 NTERPRO Fibrillar collagen 3 6.52 2.84E-04 GO_BP Multicellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 GO_BP Anatomical structure development 13 28.26 0.001069024 GO_B	SP PIR	Glycoprotein	19	41.30	1.57E-04
GO_MF Structural molecule activity 9 19.57 1.68E-04 JP_SEQ PropeptideC-terminal propeptide 3 6.52 1.83E-04 GO_BP Organ development 11 23.91 2.43E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.45E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.71E-04 NTERPRO Fibrillar collagen, C-terminal 3 6.52 2.84E-04 GO_BP Extracellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 GO_BP Multicellular organismal process 17 36.96 6.32E-04 GO_BP Anatomical structure development 13 28.26 0.001069024 JP_SEQ Domain:VWFC 3 6.52 0.001162772 GO_BP Anatomical structure organization and biogenesis 4 8.70 0.001291296 NTERPRO von Wilebrand factor, type C 3 6.52	GO BP	System development	13	28.26	1.62E-04
DP_SEQ Propeptide:C-terminal propeptide 3 6.52 1.83E-04 SO_BP Organ development I 23.91 243E-04 GO_BP Extracellular matrix organization and biogenesis I 8.70 244E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 245E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.71E-04 NTERPRO Fibrillar collagen, C-terminal 3 6.52 2.84E-04 GO_DP Muticellular organismal development 14 30.43 5.90E-04 GO_BP Muticellular organismal development 14 30.43 5.90E-04 GO_BP Muticellular organismal process 17 36.96 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 JP_SEQ Glycosylation site!N-linked (GlcNAc) 18 39.13 8.15E-04 GO_BP Anatomical structure development 13 2.826 0.001069024 JP_SEQ Domain:WFC 3 6.52	GO ME	Structural molecule activity	9	1957	L 68E-04
PPR Ehlers-Danlos syndrome 3 6.52 1.89E-04 GO_BP Organ development I 23.91 2.43E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.43E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.45E-04 GO_CC Fibrillar collagen, C-terminal 3 6.52 2.84E-04 EGG Cell communication 5 10.87 4.06E-04 GO_BP Multicellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 MART COLFI 3 6.52 7.14E-04 JP_SEQ Domain:WFC 3 6.52 0.001162772 GO_BP Anatomical structure development 13 2.826 0.0001291298 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291292	JP SEO	Propeptide:C-terminal propeptide	3	6.52	L 83E-04
Go_BP Organ development 11 23.91 2.43E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.45E-04 GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.45E-04 NTERPRO Fibrillar collagen, C-terminal 3 6.52 2.84E-04 KEGG Cell communication 5 10.87 4.06E-04 GO_BP Multicellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.66 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 MART COLFI 3 6.52 7.14E-04 JP_SEQ Disulphide bond 13 38.15E-04 00010609024 JP_SEQ Domain:VWFC 3 6.52 0.001162772 GO_BP Anatomical structure development 13 32.61 0.004219296 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291296	SP PIR	Fhlers-Danlos syndrome	3	6.52	1.89E-04
GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.45E-04 GO_CC Fibrillar collagen 3 6.52 2.71E-04 NTERPRO Fibrillar collagen, C-terminal 3 6.52 2.84E-04 GGG Cell communication 5 10.87 4.06E-04 GO_BP Multicellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 GO_BP Anatomical structure development 13 28.26 0.001069024 JP_SEQ Glycosylation site:N-linked (GlcNAc) 18 39.13 8.15E-04 GO_BP Anatomical structure development 13 28.26 0.001069024 JP_SEQ Domain:WFC 3 6.52 0.00148773 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291296 NTERPRO von Willebrand factor, type C 3 6.52 <t< td=""><td>GO BP</td><td>Organ development</td><td>-</td><td>23.91</td><td>2.43E-04</td></t<>	GO BP	Organ development	-	23.91	2.43E-04
GO_CC Fibrillar collagen 3 6.52 2.71E-04 NTERPRO Fibrillar collagen, C-terminal 3 6.52 2.84E-04 2GG Cell communication 5 10.87 4.06E-04 GO_BP Multicellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 SMART COLFI 3 6.52 7.14E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 GO_BP Anatomical structure development 13 28.26 0.0011069024 JP_SEQ Glycosylation site:N-linked (GlcNAc) 18 39.13 8.15E-04 GO_BP Anatomical structure development 13 28.26 0.001169024 JP_SEQ Domain:VWFC 3 6.52 0.001169024 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.00129129E NTERPRO von Willebrand factor, type C 3 6.52 0.003487936	GO BP	Extracellular matrix organization and biogenesis	4	8 70	2 45E-04
NTERPRO Fibrillar collagen, C-terminal 3 6.52 2.84E-04 KEGG Cell communication 5 10.87 4.06E-04 GO_BP Multicellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 SMART COLFI 3 6.52 7.14E-04 JP_SEQ Glycosylation site:N-linked (GlcNAc) 18 39.13 8.15E-04 GO_BP Anatomical structure development 13 28.26 0.001069024 JP_SEQ Domain:WVFC 3 6.52 0.001169024 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298 NTERPRO von Wilebrand factor, type C 3 6.52 0.003487936 GO_BP Developmental process 15 32.61 0.00457331 GO_MF Complement component CIs activity 2 4.35 0.000611568 <t< td=""><td></td><td>Fibrillar collagen</td><td>3</td><td>6.52</td><td>271E-04</td></t<>		Fibrillar collagen	3	6.52	271E-04
Kirls for Cell communication 5 1032 1014 1014 GG Cell communication 5 10.87 4.06E-04 GO_BP Multicellular organismal development 14 30.43 5.90E-04 GO_BP Multicellular organismal process 17 36.96 6.33E-04 JP_SEQ Disulphide bond 15 32.61 6.92E-04 SMART COLFI 3 6.52 7.14E-04 JP_SEQ Glycosylation site:N-linked (GlcNAc) 18 39.13 8.15E-04 GO_BP Anatomical structure development 13 28.26 0.001069024 JP_SEQ Domain:WFC 3 6.52 0.001162772 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298 NTERPRO von Willebrand factor, type C 3 6.52 0.003487936 GO_BP Developmental process 15 32.61 0.004417372 GO_BP Developmental process 15 32.61 0.004417372 GO_MF Complement component CIs activity 2 4.35 0.006011566	NTERPRO	Fibrillar collagen C-terminal	3	6.52	2.84E-04
Construction S 1007 1007 GO_BP Multicellular organismal development 14 30.43 5.90E–04 GO_BP Multicellular organismal process 17 36.96 6.33E–04 JP_SEQ Disulphide bond 15 32.61 6.92E–04 MART COLFI 3 6.52 7.14E–04 JP_SEQ Glycosylation site:N-linked (GlcNAc) 18 39.13 8.15E–04 GO_BP Anatomical structure development 13 28.26 0.001069024 JP_SEQ Domain:WWFC 3 6.52 0.001162772 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298 NTERPRO von Willebrand factor, type C 3 6.52 0.003487936 GO_BP Developmental process 15 32.61 0.004413792 GO_MF Complement component C1s activity 2 4.35 0.006011568 GO_CC Extracellular space 6 13.04 0.005323916 JP_SEQ Do	KEGG	Cell communication	5	10.87	4.06E-04
Solution Induction organismal occordspirate Initial organismal occordspirate Initial organismal occordspirate Initial occordspirate <thinitial occordspirate<="" th=""> Initial occor</thinitial>	GO BP	Multicellular organismal development	14	30.43	5.90E-04
DP_SEQ Disulphide bond 15 32.61 6.92 = -04 SMART COLFI 3 6.52 7.14E-04 JP_SEQ Glycosylation site:N-linked (GlcNAc) 18 39.13 8.15E-04 GO_BP Anatomical structure development 13 28.26 0.001069024 JP_SEQ Domain:WFC 3 6.52 0.001162772 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298 SO_BP Extracellular structure organization and biogenesis 4 8.70 0.003487936 GO_BP Developmental process 15 32.61 0.004413792 GO_BP Developmental process 15 32.61 0.004413792 GO_MF Complement component C1s activity 2 4.35 0.004676533 GO_CC Extracellular space 6 13.04 0.005323916 JP_SEQ Domain:/WFA 4 2 4.35 0.006011568 SMART VWC 3 6.52 0.007203275 SP_PIR	GO BP	Multicellular organismal process	17	36.96	633E-04
Dr. Stock Displace	IP SEO	Disulphide bond	15	32.61	6.92E-04
JP_SEQ Glycosylation site:N-linked (GlcNAc) I8 39.13 8.15E-04 GO_BP Anatomical structure development I3 28.26 0.001069024 JP_SEQ Domain:WFC 3 6.52 0.001162772 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298 NTERPRO von Willebrand factor, type C 3 6.52 0.003487936 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298 NTERPRO von Willebrand factor, type C 3 6.52 0.003487936 GO_BP Developmental process I5 32.61 0.004476533 GO_MF Complement component C1s activity 2 4.35 0.004676533 GO_CC Extracellular space 6 13.04 0.005323916 JP_SEQ Domain:WFA 4 2 4.35 0.006011568 SMART VWC 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842	SMART		3	652	7.14E_04
GO_BP Anatomical structure development 13 28.26 0.001069024 GO_BP Domain:WWFC 3 6.52 0.001162772 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298 NTERPRO von Willebrand factor, type C 3 6.52 0.004413792 GO_BP Developmental process 15 32.61 0.00476533 GO_CC Extracellular space 6 13.04 0.005323916 JP_SEQ Domain:WVFA 4 2 4.35 0.006011568 SMART VWC 3 6.52 0.007203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842		Glycosylation site:N-linked (GlcNIAc)	18	39.13	815E_04
JP_SEQ Domain:WWFC 3 6.52 0.00106/2772 GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298 NTERPRO von Willebrand factor, type C 3 6.52 0.00413792 GO_BP Developmental process 15 32.61 0.00413792 GO_MF Complement component C1s activity 2 4.35 0.004676533 GO_CC Extracellular space 6 13.04 0.005323916 JP_SEQ Domain:WFA 4 2 4.35 0.006011566 MART VWC 3 6.52 0.007203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842		Apstemical structure development	13	28.75	0.152-01
GO_BP Extracellular structure organization and biogenesis 4 8.72 0.001102/1298 SO_BP Extracellular structure organization and biogenesis 4 8.62 0.001291298 NTERPRO von Willebrand factor, type C 3 6.52 0.003487936 GO_BP Developmental process 15 32.61 0.004413792 GO_MF Complement component C1s activity 2 4.35 0.004676533 GO_CC Extracellular space 6 13.04 0.005323916 JJP_SEQ Domain:WVFA 4 2 4.35 0.006011568 SMART VWC 3 6.52 0.007203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842	JO_DI IP_SEO		3	6 5 7	0.001007027
SO_BR Developmental process 4 6.70 0.0012/12/C GO_BP Developmental process 15 32.61 0.00413792 GO_MF Complement component C1s activity 2 4.35 0.004676533 GO_CC Extracellular space 6 13.04 0.005323916 JP_SEQ Domain:WFA 4 2 4.35 0.00611568 SMART VWC 3 6.52 0.007203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.00814529 SP_PIR Skin 2 4.35 0.006214529		Extracellular structure organization and biogenesis	4	8 70	0.001102772
NTERRO Volt Willebrahl factor, type C 3 6.32 0.0038736 GO_BP Developmental process 15 32.61 0.00413792 GO_MF Complement component C1s activity 2 4.35 0.004676533 GO_CC Extracellular space 6 13.04 0.005323916 JP_SEQ Domain:WFA 4 2 4.35 0.006011568 SMART VWC 3 6.52 0.007203275 JP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 JP_PIR Skin 2 4.35 0.009320842		ven Willehmed factor type C	T 2	6.70	0.001271270
GO_phr Development aprocess 15 32.61 0.00447372 GO_MF Complement component C1s activity 2 4.35 0.00467633 GO_CC Extracellular space 6 13.04 0.005323916 UP_SEQ Domain:WFA 4 2 4.35 0.006011568 SMART VWC 3 6.52 0.007203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842		Developmental process	15	22.61	0.003407730
GO_INF Complement component Cristactivity 2 4.35 0.0047/833 GO_CC Extracellular space 6 13.04 0.005323916 JP_SEQ Domain:WFA 4 2 4.35 0.006011568 SMART VWC 3 6.52 0.007203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842	GO_DF	Complemental process	13	4.25	0.004413792
GO_CC Extracellular space 6 13.04 0.00322516 JP_SEQ Domain:WFA 4 2 4.35 0.006011568 SMART VWC 3 6.52 0.007203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842		Extra component CTS activity	2	4.55	0.004676333
Domain: WVFA 4 Z 4.35 0.006011568 SMART VWC 3 6.52 0.007203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842		Extracellular space	6	13.04	0.005323916
VVVC 3 6.52 0.007/203275 SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529 SP_PIR Skin 2 4.35 0.009320842	JF_SEQ	Domain:VVVFA 4	2	4.35	0.006011568
pr_rik rymolidone carboxylic acid 3 6.52 0.008914525 SP_PIR Skin 2 4.35 0.009320842	אריזא מוס מכ		3	6.52	0.007203275
or_rik Skin 2 4.35 0.009320842		Pyrrolidone carboxylic acid	5	6.52	0.008914529
	DF_PIK	SKIN	2	4.35	0.009320842

uses a set of non-differentially expressed genes to normalise data that are identified by using an iterative procedure. Gene expression common to the sorted cells and whole tissue should be reasonably uniform. Any genes found to be expressed in the whole tissue can be presumed to be contained in stromal tissue. We then sought to examine how similar the gene expression profile of each sample was. Using hierarchical clustering, all three sorted samples clustered together, as did the whole-tissue samples clustered together. Correspondence analysis also showed a clear separation of sorted samples and whole-tissue samples. The E1 and E1W sample also separated from the other samples. This is not surprising as this sample was from a more advanced tumour than the others. The stromal component of the whole-tissue sample was the biggest determinate in differences and could easily separate all samples. This may explain why some studies show very similar GEP throughout tumour stages, and the similarity of some of the genes in our whole tumour sample to that of Kwong et al (Birkenkamp-Demtroder et al, 2002; Kwong et al, 2005). Qualitatively the expression of the whole tumour samples were consistent with tumour stroma, with genes highly specific for colorectal tumour stroma (e.g., ANTXR1), and DAVID analysis identifying highly significant functional groups involved in

extracellular matrix function. Conversely, FACS-purified parenchyma expressed genes specifically associated with colorectal neoplasia, such as *HOX2D* and *RHOB*. The ability to examine the samples in parallel affords increased precision in analysis of tumour fraction gene expression and offers new opportunities to examine tumour-stroma interactions.

Fluorescence-activated cell sorting parenchymal purification has several advantages over LCM. Disaggregation of a tumour sample generates a large random sample of tumour cells and may elicit a more representative and relevant gene expression profile than LCM, without the need for RNA amplification. Previous studies have assessed the differences between LCM acquired tissue, macrodissection and whole-tissue samples for microarray studies (Sugiyama et al, 2002; Michel et al, 2003; de Bruin et al, 2005). Sugiyama suggests that if the stromal compartment is >30% LCM should be used, and showed marked differences in GEP in LCMderived tissue compared with bulk biopsy. Similarly, Michel et al (2003) demonstrated that the LCM process introduces a bias into GEP profiles. Although they found that large expression changes were maintained, many genes changed with lower expression levels may be lost. This is problematic for several reasons - particularly as smaller changes in mRNA expression may have larger effects downstream than larger ones. Also it makes comparisons difficult between studies. Although LCM aims to overcome such problems, the very premise it is built on may introduce bias. A twodimensional microscope view of a complex three-dimensional structure such as a tumour leads to irreversible qualitative and quantitative loss of information (Nyengaard, 1999). This means that fractions of cells can be grossly under- or overestimated if unbiased sampling methods such as stereological methods are not used (the 'reference trap'). At worst it can lead to a gene expression profile of 1463

a tiny fraction of tumour being misinterpreted as expression of the whole tumour. Macrodissection is subject to similar compromises. Fluorescence-activated cell sorting overcomes many of these problems by allowing systematic sampling of cells, providing a large sample of cells, which allows confirmation of purity of targets and also a better average of gene expression in a tumour.

In conclusion, FACS is effective in producing homogenous cell populations for gene expression microarray experiments in solid tumours and is viable alternative to macrodissection, LCM and whole tumour sampling in microarray experiments. Fluorescenceactivated cell sorting overcomes many of the practical and theoretical problems associated with LCM. The gene expression profile of FACS-purified tumour parenchyma is significantly different to that of clinically resected tumour biopsies. Our analysis suggests that stromal gene expression is responsible for the differential expression and makes a significant contribution to the gene expression profile of whole tumour CRC biopsies. Therefore, one should consider a purification strategy when planning solid tumour gene expression microarray experiments. Although many of the sources of technical noise and variation in gene expression microarray technology have been overcome, there remain challenges, such as the approach to tumour heterogeneity, which need to be overcome before it is accepted into clinical practice.

ACKNOWLEDGEMENTS

We thank Ms Qiong di Wu, Dr John Lawry, Ms Miriam Cotter, Professor N Parfrey and the Department of Pathology, UCC.

REFERENCES

- Ach RA, Floore A, Curry B, Lazar V, Glas AM, Pover R, Tsalenko A, Ripoche H, Cardoso F, d'Assignies MS, Bruhn L, Van't Veer LJ (2007) Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. *BMC Genomics* 8: 148
- Afanasyeva M, Georgakopoulos D, Belardi DF, Ramsundar AC, Barin JG, Kass DA, Rose NR (2004) Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: correlation with cardiac function. Am J Pathol 164: 807–815
- Allen C, Hogg N (1985) Monocytes and other infiltrating cells in human colorectal tumours identified by monoclonal antibodies. *Immunology* **55**: 289–299
- Allen C, Hogg N (1987) Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst **78:** 465–470
- Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, Laurberg S, Sorensen FB, Hagemann R, TF OR (2002) Gene expression in colorectal cancer. *Cancer Res* 62: 4352-4363
- Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. *Nature* 406: 536–540
- Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. *FEBS Lett* **573**: 83–92
- Butte A (2002) The use and analysis of microarray data. Nat Rev Drug Discov 1: 951-960
- Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. *J Clin Oncol* **26**: 729-735

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. *Lancet* **362**: 362-369

- Culhane AC, Thioulouse J, Perriere G, Higgins DG (2005) MADE4: an R package for multivariate analysis of gene expression data. *Bioinformatics* **21**: 2789–2790
- Curtin JF, Cotter TG (2004) JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. *J Biol Chem* 279: 17090-17100
- de Bruin EC, van de Pas S, Lips EH, van Eijk R, van der Zee MM, Lombaerts M, van Wezel T, Marijnen CA, van Krieken JH, Medema JP, van de Velde CJ, Eilers PH, Peltenburg LT (2005) Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. *BMC Genomics* **6**: 142
- Delarue FL, Adnane J, Joshi B, Blaskovich MA, Wang DA, Hawker J, Bizouarn F, Ohkanda J, Zhu K, Hamilton AD, Chellappan S, Sebti SM (2007) Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. *Oncogene* **26:** 633–640
- Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol* **4**: P3
- Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci USA* **95:** 14863-14868
- Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA (1996) Laser capture microdissection. *Science* **274:** 998–1001
- Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M (2001) Correspondence analysis applied to microarray data. *Proc Natl Acad Sci USA* **98:** 10781-10786

- Fukino K, Shen L, Patocs A, Mutter GL, Eng C (2007) Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. *JAMA* **297:** 2103–2111
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 5: R80
- Gershon D (2004) Microarrays go mainstream. Nat Methods 1: 263-270
- Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7: 278
- Guo J, Xiao B, Zhang X, Jin Z, Chen J, Qin L, Mao X, Shen G, Chen H, Liu Z (2004) Combined use of positive and negative immunomagnetic isolation followed by real-time RT-PCR for detection of the circulating tumor cells in patients with colorectal cancers. *J Mol Med* 82: 768–774
- Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG (2002) Relation between resistance of Philadelphiachromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. *Lancet* **359**: 481-486
- Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT (2003) Gene expression predictors of breast cancer outcomes. *Lancet* **361:** 1590-1596
- Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, Hamada K, Nakayama H, Ishitsuka H, Miyamoto T, Hirabayashi A, Uchimura S, Hamamoto Y (2003) Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. *Lancet* 361: 923-929
- Jarvis JN, Centola M (2005) Gene-expression profiling: time for clinical application? *Lancet* 365: 199-200
- Jeffery IB, Higgins DG, Culhane AC (2006) Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. *BMC Bioinformatics* 7: 359
- Kwong KY, Bloom GC, Yang I, Boulware D, Coppola D, Haseman J, Chen E, McGrath A, Makusky AJ, Taylor J, Steiner S, Zhou J, Yeatman TJ, Quackenbush J (2005) Synchronous global assessment of gene and protein expression in colorectal cancer progression. *Genomics* 86: 142-158
- Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H (1990) Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 43: 213-219
- Li C, Hung Wong W (2001) Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. *Genome Biol* 2: RESEARCH0032
- Liu ET (2007) Stromal effects in breast cancer. N Engl J Med 357: 2537-2538
- Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH (2008) Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. *J Biol Chem* 283: 529-540
- Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, Stoughton R, Burchard J, Slade D, Dai H, Bassett Jr DE, Hartwell LH, Brown PO, Friend SH (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. *Nat Med* 4: 1293-1301
- Michel C, Desdouets C, Sacre-Salem B, Gautier JC, Roberts R, Boitier E (2003) Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liver. *Am J Pathol* **163**: 2191–2199
- Moyers JS, Bilan PJ, Zhu J, Kahn CR (1997) Rad and Rad-related GTPases interact with calmodulin and calmodulin-dependent protein kinase II. *J Biol Chem* 272: 11832–11839
- Nyengaard JR (1999) Stereologic methods and their application in kidney research. J Am Soc Nephrol 10: 1100-1123

- Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C (2007) Breast-cancer stromal cells with TP53 mutations and nodal metastases. *N Engl J Med* **357**: 2543-2551
- Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. *Nat Genet* 33: 49-54
- Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR (2001) Multiclass cancer diagnosis using tumor gene expression signatures. *Proc Natl Acad Sci USA* **98**: 15149-15154
- Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. *Nat Genet* 24: 227-235
- Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. *BMC Mol Biol* 7: 3
- Seibenhener ML, Geetha T, Wooten MW (2007) Sequestosome 1/p62 more than just a scaffold. FEBS Lett 581: 175-179
- Selaru FM, Xu Y, Yin J, Zou T, Liu TC, Mori Y, Abraham JM, Sato F, Wang S, Twigg C, Olaru A, Shustova V, Leytin A, Hytiroglou P, Shibata D, Harpaz N, Meltzer SJ (2002) Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. *Gastroenterology* **122**: 606-613
- Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68-74
- Smith MJ, Coffey JC, Wang JH, Cotter TG, Redmond HP (2003) Gene expression profiling in biliary atresia. *Lancet* **361**: 971–972;
- Sugiyama Y, Sugiyama K, Hirai Y, Akiyama F, Hasumi K (2002) Microdissection is essential for gene expression profiling of clinically resected cancer tissues. Am J Clin Pathol 117: 109-116
- Suzuki A, Nakauchi H, Taniguchi H (2004) Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. *Diabetes* 53: 2143–2152
- van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. *Nature* **415**: 530–536
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009
- Vider BZ, Zimber A, Hirsch D, Estlein D, Chastre E, Prevot S, Gespach C, Yaniv A, Gazit A (1997) Human colorectal carcinogenesis is associated with deregulation of homeobox gene expression. *Biochem Biophys Res Commun* 232: 742-748
- Waguri N, Suda T, Nomoto M, Kawai H, Mita Y, Kuroiwa T, Igarashi M, Kobayashi M, Fukuhara Y, Aoyagi Y (2003) Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. *Clin Cancer Res* 9: 3004-3011
- Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22: 1564–1571
- Winegarden N (2003) Microarrays in cancer: moving from hype to clinical reality. *Lancet* **362**: 1428
- Zigeuner RE, Riesenberg R, Pohla H, Hofstetter A, Oberneder R (2000) Immunomagnetic cell enrichment detects more disseminated cancer cells than immunocytochemistry *in vitro*. J Urol **164**: 1834–1837